Pharmacy Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Statins and cancer risk

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Astellas receives fda approval for use of progra(tacrolimus) in conjunction with mycophenolate mofetil (mmf) in kidney transplant recipients
Astellas, 05/29/09

The Food and Drug Administration has granted Astellas Pharma US, Inc. approval for the use of Prograf in conjunction with mycophenolate mofetil for the prevention of organ rejection in kidney transplant recipients. Prograf is a cornerstone therapy for preventing transplant rejection in liver, kidney and heart transplant recipients. The approval came on May 2009 in response to a Supplemental New Drug Application originally submitted in 2006. Prograf's combination use with MMF for heart transplant recipients was approved by the FDA in March 2006.

<< Previous
New Analyses from 16-Year Follow-up Trial with Betaseron...

Next >>
First Phase III Data on Innovative Compound for Solid Organ...